Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer's Lyrica: "Approvable" For Three Indications, But Not Generalized Anxiety

This article was originally published in The Pink Sheet Daily

Executive Summary

The company received a "non-approvable" letter for the treatment of generalized anxiety disorder. Pfizer says it is working with FDA to resolve "open issues on all indications" for the Neurontin follow-on agent.

You may also be interested in...



Lyrica Controlled Substance Scheduling Finalized By DEA

Pfizer’s pregabalin will launch in the fall for three indications as a Schedule V controlled substance.

Lyrica Controlled Substance Scheduling Finalized By DEA

Pfizer’s pregabalin will launch in the fall for three indications as a Schedule V controlled substance.

Pfizer Lyrica Undergoing Controlled Substance Scheduling At DEA

FDA clears pregabalin for management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia. The Neurontin follow-on compound remains "approvable" for the adjunctive treatment of partial seizures in adults with epilepsy.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel